[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Low et al., 2022 - Google Patents

SARS-CoV-2 non-structural proteins and their roles in host immune evasion

Low et al., 2022

View HTML
Document ID
3546738428078899890
Author
Low Z
Zabidi N
Yip A
Puniyamurti A
Chow V
Lal S
Publication year
Publication venue
Viruses

External Links

Snippet

Coronavirus disease 2019 (COVID-19) has caused an unprecedented global crisis and continues to threaten public health. The etiological agent of this devastating pandemic outbreak is the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). COVID-19 …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins

Similar Documents

Publication Publication Date Title
Low et al. SARS-CoV-2 non-structural proteins and their roles in host immune evasion
Romano et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping
Bai et al. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation
Yadav et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19
Kumar et al. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells
El Sahili et al. Dengue virus non-structural protein 5
Zhou et al. Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2
Corona et al. Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities
Cheng et al. DDX5 RNA helicases: emerging roles in viral infection
Wu et al. Vaccines and therapies in development for SARS-CoV-2 infections
Cong et al. The interaction between nidovirales and autophagy components
Petushkova et al. Papain-like proteases as coronaviral drug targets: Current inhibitors, opportunities, and limitations
Senger et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
Majzoub et al. The innate antiviral response in animals: an evolutionary perspective from flagellates to humans
Zhand et al. COVID-19: The immune responses and clinical therapy candidates
Pereira et al. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19
Shroff et al. The molecular interplay between human coronaviruses and autophagy
Rehman et al. Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future
Mehmood et al. SARS-CoV-2: An update on genomics, risk assessment, potential therapeutics and vaccine development
Srivastava et al. Japanese Encephalitis Virus: an update on the potential antivirals and vaccines
Timmers et al. SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions
Gudima et al. Antiviral therapy of COVID-19
Bagdassarian et al. The amino-terminal region of hepatitis E virus ORF1 containing a methyltransferase (Met) and a papain-like cysteine protease (PCP) domain counteracts type I interferon response
Nidom et al. Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021
Esposito et al. Host and viral zinc-finger proteins in COVID-19